Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEvgen Pharma Share News (EVG)

Share Price Information for Evgen Pharma (EVG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
EVG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Mortgage Advice Bureau Launches Later Life

Tue, 15th Sep 2020 22:08

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Mortgage Advice Bureau Holdings PLC - Derby-based mortgage adviser - Launches Mortgage Advice Bureau Later Life, its exclusive strategic alliance with later life lending business Key Group. MAB Later Life consists of a panel of four lenders including Key's more2Life lifetime mortgage lenders. First phase of alliance involved distributing later life mortgage products through a small pilot group of existing MAB advisers, which is now being extended to firms outside the group.

----------

Botswana Diamonds PLC - Irish exploration and project development company - Posts preliminary results from next phase of Marsfontein project drilling campaign, testing historical anomaly identified as M17 to examine potential as enlargement on the M8 kimberlite dyke. Hole ID M17H001 intersects 4 metres of kimberlite from 54 to 58 metres, among the thickest kimberlite intersections at the Marsfontein - Thorny River project area so far. This warrants detailed ground geophysics. No kimberlite identified in hole ID M17H002.

----------

Gabelli Value Plus+ Trust PLC - US equities investor - Largest shareholder ACG will not support liquidation proposals. As it holds more than 25% of voting rights and the proposals would need at least 75% approval, the board will not put forward its liquidation proposals at this time. Evaluates options available. Firm had planned to put forward proposals for members' voluntary liquidation after a 66% majority of votes at its July AGM were opposed to its continuation resolution.

----------

Manolete Partners PLC - UK-focused insolvency litigation financing firm - Completes one of the larger cases in its portfolio of UK insolvency claims, which settles for gross amount of GBP15.0 million. In current trade period since March 31, has completed 40 cases, including the larger claim which will itself generate a GBP4.1 million realised gain and make an approximately GBP2.1 million contribution to net pretax profit for the current accounting period. No material write-offs sustained in Manolete case portfolio. New business develops well in five months to August, 84 new cases either acquired or funded, up 65% year-on-year.

----------

OptiBiotix Health PLC - York-based life sciences company - Enters agreement with undisclosed US company aiming to achieve large scale manufacture and commercialisation of certain SweetBiotix products. Deal grants US company exclusive worldwide licence in return for it bearing product manufacturing, marketing, and all future commercialisation costs for various SweetBiotix products. "Modes six-figure payment" to be made to OptiBiotix in singing agreement an as 12 monthly intervals until product launch. Similar payment plus royalties on on all future sales of SweetBiotix to 11 partners once US company starts selling SweetBiotix products.

----------

McKay Securities PLC - real estate investment trust focused on office, industrial and logistics markets in south east and London - Lets whole of 135 Theale Logistics Park at Junction 12 of M4 near Reading to logistics operator. New tenant agrees to 10-year FRI lease term at rend 2.0% ahead of March ERV. Letting takes McKay's contracted rental income as at March 31 up 5.3% to GBP29.8 million.

----------

President Energy PLC - oil and gas company focusing on Latin America - Concludes operations testing of EVx-1 at Rio Negro operations in Argentina. Flow rates, pressure build up support initial testing results with USD250,000 workover of old well having "proved to be excellent value". Production rates range between 25,000 to 150,000 cubic metres per day of gas with small amount of condensate. Well to be put on stream initially producing 80,000 cubic metres per day of gas. "The data obtained from the testing is now being analysed to determine the producible volume of the reservoir and its characteristics." Old PFO-33 turned into water disposal well, replacing prior well PFO-17 which ceased to be operable around 3 months ago. President: "The drilling rig is now expected to start mobilising during the course of this week for drilling operations to commence on schedule before the end of September."

----------

Tex Holdings PLC - Suffolk-based engineering and plastics manufacturing group - Applies to Financial Conduct Authority to cancel its main market shares, with the effective date of cancellation to be on or near October 13. Listing suspended April 2019 over failure to supply audited accounts for 2018 on time. Explains that: "Continued listing of the shares incurs significant cost while presenting an obstacle to potential sources of funding."

----------

Eden Research PLC - biopesticides and plastic-free formulation technology company - Obtains patent in Australia for its Sustaine encapsulation technology. Patent is for the use of Sustaine biodegradable micro-spheres produced from yeast extract - and is the first patent anywhere in the world specifically covering the use of Sustaine with third party active ingredients.

----------

Emmerson PLC - Morocco-focused potash development company - Says "multiple workstreams in progress" for further de-risking of its Khemisset potash project. Permitting process on track with main permits set to be in place in the first half of 2021. Investigating operations for staged development so cut upfront capital costs and provides financing flexibility. Talks with possible strategic partners, anchor investors, debt providers, going well.

----------

Evgen Pharma PLC - Liverpool-headquartered clinical-stage drug development company - Licences its sulforaphane stabilisation technology for use in various non-pharmaceutical applications to Juvenescence Ltd. Juvenescence plans to market and sell a high-end nutritional health product containing sulforaphane extracted from natural sources. Evgen to receive milestone and option payments totalling maximum USD10.5 million plus royalties on future product sales. Initial payment of USD250,000 on signing of agreement.

----------

Amryt Pharma PLC - pharmaceutical company - Notes positive opinion on orphan designation for drug AP103 in Epidermolysis Bullosa from European Medicines Agency's Committee for Orphan Medicinal Products. Orphan drug destination in EU granted within 30 days of positive COMP opinion. Amryt notes: "This designation provides certain regulatory and financial incentives including but not limited to product market exclusivity for ten years in the EU following regulatory approval." Epidermolysis Bullosa is a genetic skin disorder causing skin layers and internal body lining to separate and currently has no approved treatments.

----------

HML Holdings PLC - Surrey-based property management services firm - AIM delisting expected to occur October 13 without requirement for shareholder resolution approval. This follows acceptance of offer by BDO Nominee Co Ltd to acquire company for GBP19.0 million in total. BDO will purchase shares for 37.5 pence each. BDO Nominee is a company formed under direction of Harwood Capital LLP for the purpose of making the offer.

----------

Chesterfield Resources PLC - copper-gold exploration and development company active in Cyprus - Begins diamond drill programme at Troodos West copper-gold exploration licences in Cyprus. Intending to drill a 2,000 metre programme consisting of holes of around 150 metres each, with programme set to last until around October end. Will simultaneously carry out an AMT geophysics survey plus percussion drilling in integrated exploration programme. Goal is to discover and test volcanognic massive sulphide deposits buried at shallow depth in an area of historic mines.

----------

Symphony Environmental Technologies PLC - Borehamwood-based developer of additives to make ordinary plastic biodegradable - Receives notice from Vincel Investment Holdings Ltd to exercise warrants representing 5.0 million share. Warrants granted July 19. Symphony to receive GBP1.0 million in cash proceeds.

----------

TP Group PLC - Reading-based consulting, software and engineering services provider - Receives new orders totalling around GBP4.0 million from UK Ministry of Defence to supply oxygen generation and carbon dioxide removal devices. Orders are part of GBP22 million framework agreement previously announced in April 2017. Devised to be supplied to Royal Navy in fourth quarter of 2020 and into 2021.

----------

Distil PLC - London-based owner of premium drinks brand Diva Vodka plus others - Launches RedLeg Banana Rum, second flavour extension for its Redleg Rum brand. Conducts branding refresh across range.

----------

Haydale Graphene Industries PLC - Ammanford, Wales-based nanomaterial producer - Inks contracts to provides services for the collaborative development of graphene and nano material-enhanced products for use in Dowty Propellers products. Haydale and Dowty to collaborate on developing erosion-resistant coating with addition of Haydale's Silicone Carbide Microfibers as well as other products.

----------

Boku Inc - US-based mobile payments solution provider - Recently acquires subsidiary Fortumo working with Amazon.com Inc to allow launch of Amazon Prime bundle service for Jio Platforms subscribers. Jio is a digital services company in India and is offering 1 year of Amazon Prime with select broadband plans.

----------

Galileo Resources PLC -miner with projects in Botswana, Zambia and South Africa - Announces conditional acquisition of Africibum Co Pty Ltd and its interests in Botswana's North East Kalahari Copper Belt project. Consideration is 42.0 million Galileo shares priced at 0.779 pence each.

----------

Merian Chrysalis Investment Co Ltd - London-based investor in later stage private companies - Confirms that asset referred to in Friday announcement of approximately GBP23 million follow-on investment was Klarna Holding AB. Klarna has conducted a USD650 million primary funding round with an additional secondary sell-down by some investors, with round valuing Klarna at USD10.65 billion, up from USD5.5 billion in August 2019. Merian Chrysalis gross cash position now approximately GBP31 million with Klarna stake worth around GBP96 million.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.